Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/31369
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wiendl, Heinz | - |
dc.contributor.author | Carraro, Matthew | - |
dc.contributor.author | Comi, Giancarlo | - |
dc.contributor.author | Izquierdo, Guillermo | - |
dc.contributor.author | Kim, Ho Jin | - |
dc.contributor.author | Sharrack, Basil | - |
dc.contributor.author | Tornatore, Carlo | - |
dc.contributor.author | Daizadeh, Nadia | - |
dc.contributor.author | Chung, Luke | - |
dc.contributor.author | Jacobs, Alan K. | - |
dc.contributor.author | Hogan, Richard J. | - |
dc.contributor.author | Wychowski, Linda V. | - |
dc.contributor.author | VAN WIJMEERSCH, Bart | - |
dc.date.accessioned | 2020-07-01T12:54:20Z | - |
dc.date.available | 2020-07-01T12:54:20Z | - |
dc.date.issued | 2020 | - |
dc.date.submitted | 2020-06-23T11:49:38Z | - |
dc.identifier.citation | NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 7 (1) | - |
dc.identifier.uri | http://hdl.handle.net/1942/31369 | - |
dc.description.abstract | ObjectiveTo examine the association between peripheral blood lymphocyte pharmacodynamics and autoimmune adverse events (AEs) or return of disease activity in alemtuzumab-treated patients with relapsing-remitting MS.MethodsPatients received 2 alemtuzumab courses (12 mg/d IV; 5 days at baseline, 3 days 12 months later) in the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis studies (NCT00530348 and NCT00548405) and could then receive as-needed alemtuzumab or other disease-modifying therapy in a 4-year extension (NCT00930553). Lymphocytes were phenotyped quarterly over 2 years using fluorescence-activated cell sorting. Pharmacodynamic assessments included counts of total lymphocytes, CD3(+) T cells, CD4(+)/CD8(+) T cells (total/naive/memory/regulatory [T-reg]), and CD19(+) B cells (total/immature/mature/memory) and ratios of CD19(+) (total/immature/mature/memory) to T-reg (CD4(+)/CD8(+)) counts. Assessed autoimmune AEs included immune thrombocytopenia, nephropathies, and thyroid events. Efficacy assessments included relapses, 6-month confirmed disability worsening (CDW), and MRI disease activity.ResultsLymphocyte repopulation patterns, including ratios between distinct lymphocyte subsets (e.g., CD19(+) to T-reg cell count ratios), showed no significant differences over 2 years in patients developing/not developing autoimmune AEs, relapses, CDW, or MRI activity through 6 years following alemtuzumab. Lymphocyte kinetics were also unrelated to multiple autoimmune AEs or extreme clinical phenotypes.ConclusionsRepopulation kinetics of the evaluated peripheral lymphocyte subsets did not predict autoimmune AE occurrence or disease activity, including return of disease activity after 2 alemtuzumab courses. Further study is needed to investigate potential antigen-level markers of treatment response. | - |
dc.description.sponsorship | This study was supported by Sanofi and Bayer HealthCare Pharmaceuticals. Prof. H. Wiendl was supported by the Deutsche Forschungsgemeinschaft (DFG) Grant CRC128 Project A09, and the Kompetenznetz Multiple Sklerose (Competence Network for Multiple Sclerosis) funded by the Federal Ministry of Education and Research (FKZ 01GI1308B 01GI0907). | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.rights | This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. | - |
dc.subject.other | Remitting Multiple-Sclerosis | - |
dc.subject.other | Depletion | - |
dc.subject.other | Therapy | - |
dc.subject.other | Update | - |
dc.subject.other | Cells | - |
dc.title | Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 1 | - |
dc.identifier.volume | 7 | - |
local.format.pages | 10 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Wiendl, H (reprint author), Univ Munster, Munster, Germany. | - |
dc.description.notes | heinz.wiendl@ukmuenster.de | - |
dc.description.other | Wiendl, H (corresponding author), Univ Munster, Munster, Germany. heinz.wiendl@ukmuenster.de | - |
local.publisher.place | TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.source.type | Article | - |
dc.identifier.doi | 10.1212/NXI.0000000000000635 | - |
dc.identifier.pmid | 31662412 | - |
dc.identifier.isi | WOS:000530690100003 | - |
dc.identifier.eissn | - | |
local.provider.type | wosris | - |
local.uhasselt.uhpub | yes | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.fullcitation | Wiendl, Heinz; Carraro, Matthew; Comi, Giancarlo; Izquierdo, Guillermo; Kim, Ho Jin; Sharrack, Basil; Tornatore, Carlo; Daizadeh, Nadia; Chung, Luke; Jacobs, Alan K.; Hogan, Richard J.; Wychowski, Linda V. & VAN WIJMEERSCH, Bart (2020) Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. In: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 7 (1). | - |
item.validation | ecoom 2021 | - |
item.contributor | Wiendl, Heinz | - |
item.contributor | Carraro, Matthew | - |
item.contributor | Comi, Giancarlo | - |
item.contributor | Izquierdo, Guillermo | - |
item.contributor | Kim, Ho Jin | - |
item.contributor | Sharrack, Basil | - |
item.contributor | Tornatore, Carlo | - |
item.contributor | Daizadeh, Nadia | - |
item.contributor | Chung, Luke | - |
item.contributor | Jacobs, Alan K. | - |
item.contributor | Hogan, Richard J. | - |
item.contributor | Wychowski, Linda V. | - |
item.contributor | VAN WIJMEERSCH, Bart | - |
crisitem.journal.issn | 2332-7812 | - |
crisitem.journal.eissn | 2332-7812 | - |
Appears in Collections: | Research publications |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.